According to our (Global Info Research) latest study, the global Anticancer Biologics market size was valued at US$ 114684 million in 2025 and is forecast to a readjusted size of US$ 217860 million by 2032 with a CAGR of 9.0% during review period.
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
Report Scope
This report is a detailed and comprehensive analysis for global Anticancer Biologics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anticancer Biologics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Anticancer Biologics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Anticancer Biologics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Anticancer Biologics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anticancer Biologics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anticancer Biologics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Roche, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Anticancer Biologics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
Antibody Therapies
Antibody-Drug Conjugates (ADCs)
Cell Therapies
Cancer Vaccines and Oncolytic Viruses
Others
Market segment by Target
Immune Checkpoint Targets
Solid Tumor-Associated Targets
Hematologic Tumor Targets
Angiogenesis-Related Targets
Others
Market segment by Route of Administration
Intravenous Administration
Subcutaneous Administration
Cell Infusion
Intratumoral Administration
Others
Market segment by Application
Lung Cancer
Breast Cancer
Hematologic Cancers
Gastrointestinal Cancers
Others
Market segment by players, this report covers
AbbVie Inc.
Johnson & Johnson
Novartis AG
Gilead Sciences, Inc.
Roche
Bristol-Myers Squibb Company
Amgen Inc.
AstraZeneca plc
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Merck KGaA
Eli Lilly and Company
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
GSK plc
Regeneron Pharmaceuticals, Inc.
Innovent Biologics, Inc.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd.
Akeso, Inc.
Shanghai Henlius Biotech, Inc.
RemeGen Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sino Biopharmaceutical Limited
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Anticancer Biologics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anticancer Biologics, with revenue, gross margin, and global market share of Anticancer Biologics from 2021 to 2026.
Chapter 3, the Anticancer Biologics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Anticancer Biologics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Anticancer Biologics.
Chapter 13, to describe Anticancer Biologics research findings and conclusion.
Summary:
Get latest Market Research Reports on Anticancer Biologics. Industry analysis & Market Report on Anticancer Biologics is a syndicated market report, published as Global Anticancer Biologics Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Anticancer Biologics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.